OpenLB
Open Library of Bioscience
Advanced Search
Clinical microbiology reviews
09 21, 2022;35 (3): e0022721.

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.

Jan Heyckendorf, Sophia B Georghiou, Nicole Frahm, Norbert Heinrich, Irina Kontsevaya, Maja Reimann, David Holtzman, Marjorie Imperial, Daniela M Cirillo, Stephen H Gillespie, Morten Ruhwald, UNITE4TB Consortium
Author Information
  1. Jan Heyckendorf: Department of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
  2. Sophia B Georghiou: FIND, the Global Alliance for Diagnostics, Geneva, Switzerland.
  3. Nicole Frahm: Bill & Melinda Gates Medical Research Institute, Cambridge, Massachusetts, USA.
  4. Norbert Heinrich: Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich (LMU), Munich, Germany.
  5. Irina Kontsevaya: Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
  6. Maja Reimann: Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
  7. David Holtzman: FIND, the Global Alliance for Diagnostics, Geneva, Switzerland.
  8. Marjorie Imperial: University of California San Francisco, San Francisco, California, USA, United States.
  9. Daniela M Cirillo: Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. ORCID
  10. Stephen H Gillespie: School of Medicine, University of St Andrewsgrid.11914.3c, St Andrews, Fife, Scotland.
  11. Morten Ruhwald: FIND, the Global Alliance for Diagnostics, Geneva, Switzerland. ORCID
PMID: 35311552 DOI: 10.1128/cmr.00227-21

Abstract

Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a global public health threat. A significant challenge for TB control efforts has been the monitoring of TB therapy and determination of TB treatment success. Current recommendations for TB treatment monitoring rely on sputum and culture conversion, which have low sensitivity and long turnaround times, present biohazard risk, and are prone to contamination, undermining their usefulness as clinical treatment monitoring tools and for drug development. We review the pipeline of molecular technologies and assays that serve as suitable substitutes for current culture-based readouts for treatment response and outcome with the potential to change TB therapy monitoring and accelerate drug development.

Keywords

biomarkers outcome treatment monitoring tuberculosis

References

  1. JCI Insight. 2020 May 21;5(10): [PMID: 32369456]
  2. Int J Infect Dis. 2020 Jul;96:244-253 [PMID: 32353548]
  3. EBioMedicine. 2017 Nov;25:112-121 [PMID: 29100778]
  4. Thorax. 2010 Oct;65(10):863-9 [PMID: 20861290]
  5. Am J Respir Crit Care Med. 2014 Aug 15;190(4):374-83 [PMID: 24941306]
  6. Clin Infect Dis. 2016 Apr 15;62(8):995-1001 [PMID: 26908793]
  7. Eur Respir J. 2018 Nov 8;52(5): [PMID: 30361242]
  8. J Microbiol Methods. 2001 May;45(1):41-52 [PMID: 11295196]
  9. Sci Rep. 2019 Oct 18;9(1):15000 [PMID: 31628424]
  10. Sci Rep. 2020 May 6;10(1):7647 [PMID: 32376992]
  11. J Clin Med. 2019 Dec 31;9(1): [PMID: 31906163]
  12. Front Microbiol. 2019 Jun 26;10:1441 [PMID: 31297103]
  13. J Clin Med. 2018 Dec 17;7(12): [PMID: 30562940]
  14. Lancet Respir Med. 2013 Aug;1(6):427-8 [PMID: 24429228]
  15. BMC Infect Dis. 2017 Apr 8;17(1):251 [PMID: 28388895]
  16. Front Microbiol. 2019 Dec 18;10:2789 [PMID: 31921004]
  17. Open Forum Infect Dis. 2018 Oct 10;5(11):ofy253 [PMID: 30474046]
  18. J Clin Invest. 2020 Nov 2;130(11):5756-5764 [PMID: 32692731]
  19. PLoS Med. 2020 May 1;17(5):e1003113 [PMID: 32357197]
  20. PLoS One. 2019 Jun 13;14(6):e0217963 [PMID: 31194793]
  21. N Engl J Med. 2021 May 6;384(18):1705-1718 [PMID: 33951360]
  22. Clin Microbiol Infect. 2020 Nov;26(11):1488-1492 [PMID: 32750539]
  23. Mol Microbiol. 2003 Jan;47(2):529-38 [PMID: 12519202]
  24. Tuberculosis (Edinb). 2020 Mar;121:101915 [PMID: 32279871]
  25. Front Microbiol. 2020 Sep 22;11:550760 [PMID: 33072011]
  26. Lancet Infect Dis. 2021 Mar;21(3):354-365 [PMID: 33508224]
  27. Int J Tuberc Lung Dis. 2010 May;14(5):560-70 [PMID: 20392348]
  28. Nat Commun. 2021 May 18;12(1):2899 [PMID: 34006838]
  29. Quant Imaging Med Surg. 2013 Apr;3(2):89-99 [PMID: 23630656]
  30. PLoS Negl Trop Dis. 2016 May 18;10(5):e0004701 [PMID: 27192147]
  31. Radiology. 2017 Aug;284(2):574-582 [PMID: 28436741]
  32. PLoS One. 2012;7(5):e36886 [PMID: 22606304]
  33. Front Immunol. 2020 Oct 08;11:566608 [PMID: 33117351]
  34. PLoS Med. 2019 Apr 12;16(4):e1002780 [PMID: 30978194]
  35. PLoS Med. 2007 Jul 24;4(7):e238 [PMID: 17676945]
  36. N Engl J Med. 2016 Sep 15;375(11):1103-5 [PMID: 27626539]
  37. J Infect. 2017 Nov;75(5):441-447 [PMID: 28804027]
  38. Expert Rev Anti Infect Ther. 2014 Feb;12(2):223-37 [PMID: 24392698]
  39. PLoS One. 2016 Aug 10;11(8):e0160062 [PMID: 27508390]
  40. Open Forum Infect Dis. 2020 Jun 06;7(7):ofaa218 [PMID: 32733976]
  41. J Antimicrob Chemother. 2015 Oct;70(10):2823-7 [PMID: 26163401]
  42. Int J Infect Dis. 2015 Mar;32:87-93 [PMID: 25809762]
  43. Ann Lab Med. 2014 May;34(3):203-9 [PMID: 24790907]
  44. Nature. 2010 Aug 19;466(7309):973-7 [PMID: 20725040]
  45. Am J Respir Crit Care Med. 2009 Sep 15;180(6):558-63 [PMID: 19542476]
  46. Expert Rev Respir Med. 2016 Jun;10(6):643-54 [PMID: 27030924]
  47. Front Immunol. 2018 Sep 28;9:2247 [PMID: 30323818]
  48. Biochem Biophys Res Commun. 2018 Sep 18;503(4):2263-2270 [PMID: 29959917]
  49. J Infect. 2017 Apr;74(4):367-376 [PMID: 28017825]
  50. Eur Respir J. 2021 Jan 5;57(1): [PMID: 32732329]
  51. Nat Med. 2018 Nov;24(11):1708-1715 [PMID: 30397355]
  52. Korean J Intern Med. 2020 Sep;35(5):1145-1153 [PMID: 32066222]
  53. EBioMedicine. 2020 Oct;60:103007 [PMID: 32949995]
  54. Clin Nucl Med. 2016 Apr;41(4):e187-94 [PMID: 26704732]
  55. Eur Respir J. 2021 Jan 5;57(1): [PMID: 32764113]
  56. J Clin Invest. 2015 May;125(5):1827-38 [PMID: 25822019]
  57. Chest. 2010 Jan;137(1):122-8 [PMID: 19749004]
  58. Tuberculosis (Edinb). 2017 Dec;107:48-58 [PMID: 29050771]
  59. Front Immunol. 2021 Feb 10;11:596173 [PMID: 33643286]
  60. Scand J Infect Dis. 2008;40(2):111-20 [PMID: 17852907]
  61. J Infect. 2020 Jul;81(1):57-71 [PMID: 32330526]
  62. Lancet Microbe. 2021 May;2(5):e169-e170 [PMID: 33778790]
  63. BMC Microbiol. 2016 Jul 28;16(1):167 [PMID: 27464737]
  64. J Clin Microbiol. 2015 Jun;53(6):1908-14 [PMID: 25854485]
  65. Radiology. 1993 Mar;186(3):653-60 [PMID: 8430169]
  66. J Clin Microbiol. 2019 Jun 25;57(7): [PMID: 31018981]
  67. BMC Infect Dis. 2019 Dec 11;19(1):1048 [PMID: 31829183]
  68. Mucosal Immunol. 2021 Mar;14(2):491-499 [PMID: 32678272]
  69. Int J Infect Dis. 2019 Feb;79:65-71 [PMID: 30395979]
  70. J Clin Microbiol. 2019 Mar 28;57(4): [PMID: 30728191]
  71. Lancet. 2018 Sep 8;392(10150):821-834 [PMID: 30215381]
  72. Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419845176 [PMID: 31012357]
  73. Lancet Respir Med. 2013 Aug;1(6):462-70 [PMID: 24429244]
  74. Am J Respir Crit Care Med. 2016 Dec 15;194(12):1532-1540 [PMID: 27387272]
  75. J Clin Microbiol. 2020 Sep 22;58(10): [PMID: 32727827]
  76. Clin Infect Dis. 2016 Oct 1;63(7):e147-e195 [PMID: 27516382]
  77. Methods Mol Biol. 2017;1616:89-105 [PMID: 28600763]
  78. JACS Au. 2021 Jul 26;1(9):1368-1379 [PMID: 34604847]
  79. Tuberculosis (Edinb). 2016 Jul;99:143-146 [PMID: 27450016]
  80. Eur J Clin Microbiol Infect Dis. 2010 Dec;29(12):1561-5 [PMID: 20820832]
  81. Cytometry A. 2020 Jul;97(7):683-693 [PMID: 32437069]
  82. J Clin Microbiol. 2014 Aug;52(8):3064-7 [PMID: 24871215]
  83. Clin Infect Dis. 2021 Nov 2;73(9):e3520-e3528 [PMID: 33070176]
  84. Ther Drug Monit. 2021 Feb 1;43(1):108-115 [PMID: 32956238]
  85. Eur Respir J. 2012 Nov;40(5):1211-20 [PMID: 22362849]
  86. J Exp Med. 1993 Dec 1;178(6):2249-54 [PMID: 7504064]
  87. Int J Tuberc Lung Dis. 2011 Jul;15(7):871-85 [PMID: 21496360]
  88. Eur Respir J. 2021 Sep 2;58(3): [PMID: 33574078]
  89. Lancet Infect Dis. 2021 Mar;21(3):366-375 [PMID: 33508221]
  90. Sci Rep. 2020 May 25;10(1):8629 [PMID: 32451443]
  91. PLoS One. 2014 Mar 19;9(3):e92340 [PMID: 24647646]
  92. Thorax. 2008 May;63(5):440-6 [PMID: 17615085]
  93. Sci Rep. 2019 Dec 10;9(1):18669 [PMID: 31822686]
  94. N Engl J Med. 2018 Aug 30;379(9):823-833 [PMID: 30157391]
  95. Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):632-9 [PMID: 19093113]
  96. Am J Respir Crit Care Med. 2021 Nov 1;204(9):1086-1096 [PMID: 34346856]
  97. EBioMedicine. 2019 Aug;46:202-214 [PMID: 31401197]
  98. Tuberculosis (Edinb). 2014 Jul;94(4):421-7 [PMID: 24863654]
  99. Sci Transl Med. 2014 Dec 3;6(265):265ra166 [PMID: 25473034]
  100. Tuberculosis (Edinb). 2019 Sep;118:101859 [PMID: 31434026]
  101. Thorax. 2020 Jul;75(7):606-608 [PMID: 32354738]
  102. PLoS One. 2012;7(10):e46191 [PMID: 23056259]
  103. Jpn J Infect Dis. 2019 Jan 23;72(1):19-22 [PMID: 30270248]
  104. Int J Tuberc Lung Dis. 2014 Mar;18(3):341-6 [PMID: 24670573]
  105. Tuberculosis (Edinb). 2016 Jul;99:131-142 [PMID: 27450015]
  106. Cytokine X. 2020 May 13;2(2):100028 [PMID: 33604556]
  107. Cochrane Database Syst Rev. 2016 May 10;(5):CD011420 [PMID: 27163343]
  108. J Clin Microbiol. 2018 Nov 27;56(12): [PMID: 30257899]
  109. Int J Mycobacteriol. 2018 Oct-Dec;7(4):299-309 [PMID: 30531026]
  110. BMC Res Notes. 2021 Jun 30;14(1):247 [PMID: 34193258]
  111. Gates Open Res. 2017 Nov 6;1:9 [PMID: 29528048]
  112. Lancet Infect Dis. 2016 Apr;16(4):e34-46 [PMID: 27036358]
  113. Eur Respir J. 2016 Jun;47(6):1873-6 [PMID: 27076596]
  114. BMC Med. 2018 May 21;16(1):73 [PMID: 29779492]
  115. Eur Respir J. 2018 Mar 22;51(3): [PMID: 29567725]
  116. Front Pediatr. 2019 Feb 11;7:27 [PMID: 30805325]
  117. Tuberculosis (Edinb). 2015 Dec;95(6):639-650 [PMID: 26515270]
  118. Lancet Respir Med. 2016 Mar;4(3):213-24 [PMID: 26907218]
  119. Nature. 2021 Jun;594(7862):265-270 [PMID: 34040261]
  120. J Clin Microbiol. 2015 Apr;53(4):1301-9 [PMID: 25673798]
  121. Infect Dis Rep. 2012 Jan 18;4(1):e10 [PMID: 24470917]
  122. Int J Tuberc Lung Dis. 2012 Sep;16(9):1180-5 [PMID: 22794271]
  123. Sci Rep. 2015 Oct 26;5:15615 [PMID: 26499913]
  124. Annu Rev Immunol. 2002;20:581-620 [PMID: 11861613]
  125. J Clin Microbiol. 2016 Aug;54(8):2058-67 [PMID: 27225403]
  126. Am J Respir Crit Care Med. 2004 Nov 15;170(10):1124-30 [PMID: 15374844]
  127. BMJ Open. 2015 Apr 15;5(4):e006833 [PMID: 25877271]
  128. PLoS One. 2020 Jan 3;15(1):e0227100 [PMID: 31899769]
  129. Nat Med. 2016 Oct;22(10):1094-1100 [PMID: 27595324]
  130. J Clin Microbiol. 2016 Dec;54(12):3028-3033 [PMID: 27733634]
  131. Int J Tuberc Lung Dis. 2018 Apr 1;22(4):399-406 [PMID: 29562987]
  132. J Med Microbiol. 2018 Dec;67(12):1718-1727 [PMID: 30388066]
  133. J Infect Dis. 2013 Jan 1;207(1):18-29 [PMID: 22872737]
  134. J Infect Dis. 2015 Apr 1;211 Suppl 2:S39-49 [PMID: 25765105]
  135. Appl Environ Microbiol. 2014 Oct;80(19):5884-91 [PMID: 25038100]
  136. Clin Pharmacol Ther. 2017 Aug;102(2):321-331 [PMID: 28124478]
  137. Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):E62-E71 [PMID: 29255022]
  138. Indian J Tuberc. 2019 Jan;66(1):134-138 [PMID: 30797271]
  139. Genome Med. 2019 Jul 25;11(1):45 [PMID: 31345251]
  140. Eur Respir J. 2011 Dec;38(6):1398-405 [PMID: 21700601]
  141. Lancet. 2016 Jun 4;387(10035):2312-2322 [PMID: 27017310]
  142. PLoS One. 2020 Jan 24;15(1):e0224445 [PMID: 31978149]
  143. Scand J Infect Dis. 2013 Nov;45(11):825-36 [PMID: 24041274]
  144. Int J Tuberc Lung Dis. 2012 Jul;16(7):928-33 [PMID: 22583610]
  145. BMC Infect Dis. 2010 Jun 08;10:161 [PMID: 20529335]
  146. Int J Tuberc Lung Dis. 2012 Oct;16(10):1335-43 [PMID: 23107633]
  147. J Clin Microbiol. 2011 Nov;49(11):3905-11 [PMID: 21900522]
  148. Tuberculosis (Edinb). 2019 Dec;119:101864 [PMID: 31568973]
  149. J Clin Microbiol. 2021 Mar 19;59(4): [PMID: 33536294]
  150. Respir Res. 2018 Dec 27;19(1):259 [PMID: 30587190]
  151. Sci Transl Med. 2021 Feb 3;13(579): [PMID: 33536283]
  152. J Infect Dis. 2012 May 15;205 Suppl 2:S250-7 [PMID: 22448027]
  153. EJNMMI Res. 2020 Feb 10;10(1):8 [PMID: 32040770]
  154. Lancet Respir Med. 2015 Mar;3(3):201-9 [PMID: 25726085]

MeSH Term

Antitubercular Agents
Hazardous Substances
Humans
Mycobacterium tuberculosis
Treatment Outcome
Tuberculosis

Chemicals

Antitubercular Agents
Hazardous Substances
Journal Article Review Research Support, Non-U.S. Gov't
Article has an altmetric score of 9

Word Cloud

Created with Highcharts 10.0.0TBmonitoringtreatmenttuberculosistherapydrugdevelopmentoutcomeNewDespiteadventnewdiagnosticsdrugsregimensremainsglobalpublichealththreatsignificantchallengecontroleffortsdeterminationsuccessCurrentrecommendationsrelysputumcultureconversionlowsensitivitylongturnaroundtimespresentbiohazardriskpronecontaminationunderminingusefulnessclinicaltoolsreviewpipelinemoleculartechnologiesassaysservesuitablesubstitutescurrentculture-basedreadoutsresponsepotentialchangeaccelerateTuberculosisTreatmentMonitoringOutcomeMeasures:InterestStrategiesbiomarkers

Similar Articles

Cited By